Last reviewed · How we verify
NCT03505242
Application of Bronchial Blocker in Minimally Invasive Cardiac Surgery
NA trial testing bronchial blocker for BB group in Minimally Invasive Cardiac Surgery in 48 participants. Status unknown.
1 May 2020
Quick facts
| Lead sponsor | Shanghai Zhongshan Hospital |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 48 |
| Start date | 1 May 2018 |
| Primary completion | 1 May 2020 |
| Estimated completion | 1 May 2020 |
Drugs / interventions tested
- bronchial blocker for BB group
- double lumen tube for DLT group
Conditions studied
- Minimally Invasive Cardiac Surgery — all drugs for Minimally Invasive Cardiac Surgery →
Sponsor
Shanghai Zhongshan Hospital
Who can join
Adults 18 to 70, any sex, with Minimally Invasive Cardiac Surgery. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Both left single lung ventilation by left double lumen tube and bilateral ventilation with selective blockage of right middle lower lobe by bronchial blocker can provide suitable surgical field for minimally invasive cardiac surgery. The current study was designed to compare the impact of these two different methods on oxygenation, degree of pulmonary collapse and postoperative complications.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Selective right middle and lower lobar blockade for minimally invasive cardiac surgery: a prospective, single-center, randomized controlled study.
Ren Y, Lyu Y, Yu Y, Jin L, et al · · 2021 · cited 7× · PMID 33708881 · DOI 10.21037/atm-20-986
Verify or expand the search:
- PubMed search for NCT03505242
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Minimally Invasive Cardiac Surgery
Currently open trials in the same condition.
- NCT07259824 — SPSIP Block and Opioid Use After MICS · NA · recruiting
- NCT07172620 — Safety and Effectiveness of No-touch Technique for Ascending Aorta in MICS-CABG · recruiting
Other Shanghai Zhongshan Hospital trials
Trials by the same sponsor.
- NCT07353476 — Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLC · Phase 2 · not yet recruiting
- NCT07508956 — Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric · Phase 3 · not yet recruiting
- NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting
- NCT07531368 — BBAP With CS Mapping Guidance · NA · not yet recruiting
- NCT07501104 — Neoadjuvant Pucotenlimab Combined With Lenvatinib and Temozolomide in Resectable Stage IIB/III Acral Melanoma · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03505242 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Zhongshan Hospital
- Last refreshed: 23 April 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03505242.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing